Abstract
This is one of the first studies to compare the frequencies of different human leucocyte antigen (HLA) class I and II alleles and haplotype HLA-DRB1*15-DQB1*06 in a cohort of 119 patients with multiple sclerosis (MS) and a cohort of 124 healthy controls in Belgium. An association with MS was found for the HLA-DRB1*15 (odds ratio [OR] 2.60 [95% confidence interval (CI) 1.51–4.50]) and HLA-DQB1*06 (OR 1.97 [95% CI 1.18–3.29]) alleles, and for haplotype DRB1*15-DQB1*06 (OR 2.63 [95% CI 1.52–4.56]). The HLA-B*07 allele also tended to be more frequent in MS patients (OR 1.46 [95% CI 0.80–2.65]) and more frequent among MS patients with than in those without the HLA-DRB1*15 allele (26/54 [48.1%] versus 6/65 [9.2%]; p value <0.0001). Other alleles were underrepresented in MS patients, such as the HLA-DRB1*07 (OR 0.39 [95% CI 0.21–0.73]) and HLA-A*02 (OR 0.56 [95% CI 0.34–0.94]), showing a protective role against the disease. The HLA-B*44 (OR 0.58 [95% CI 0.31–1.09]) and HLA-DRB1*04 (OR 0.75 [95% CI 0.42–1.34]) alleles tended to be less frequent in MS patients. Altogether, the significant results observed in this population are in line with those from other countries and confirm that propensity to MS can be due to a complex presence of various HLA class I and class II alleles.
Similar content being viewed by others
References
Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, Milanov I (2006) The epidemiology of multiple sclerosis in Europe. Eur J Neurol 13:700–722. doi:10.1111/j.1468-1331.2006.01342.x
Evans C, Beland SG, Kulaga S, Wolfson C, Kingwell E, Marriott J, Koch M, Makhani N, Morrow S, Fisk J, Dykeman J, Jette N, Pringsheim T, Marrie RA (2013) Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology 40:195–210. doi:10.1159/000342779
International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB et al (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:214–219. doi:10.1038/nature10251
Koch-Henriksen N, Sorensen PS (2010) The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 9:520–532. doi:10.1016/S1474-4422(10)70064-8
Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL (2008) The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 9:516–526. doi:10.1038/nrg2395
Kamm CP, Uitdehaag BM, Polman CH (2014) Multiple sclerosis: current knowledge and future outlook. Eur Neurol 72:132–141. doi:10.1159/000360528
Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D’Alfonso S, Martinelli-Boneschi F, Taylor B et al (2013) Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 45:1353–1360. doi:10.1038/ng.2770
Dyment DA, Herrera BM, Cader MZ, Willer CJ, Lincoln MR, Sadovnick AD, Risch N, Ebers GC (2005) Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 14:2019–2026. doi:10.1093/hmg/ddi206
Link J, Kockum I, Lorentzen AR, Lie BA, Celius EG, Westerlind H, Schaffer M, Alfredsson L, Olsson T, Brynedal B, Harbo HF, Hillert J (2012) Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis. PLoS One 7:e36779. doi:10.1371/journal.pone.0036779
Ramagopalan SV, Morris AP, Dyment DA, Herrera BM, DeLuca GC, Lincoln MR, Orton SM, Chao MJ, Sadovnick AD, Ebers GC (2007) The inheritance of resistance alleles in multiple sclerosis. PLoS Genet 3:1607–1613. doi:10.1371/journal.pgen.0030150
Zhang Q, Lin CY, Dong Q, Wang J, Wang W (2011) Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of non-family-based studies. Autoimmun Rev 10:474–481. doi:10.1016/j.autrev.2011.03.003
Michalik J, Cierny D, Kantorova E, Kantorova D, Juraj J, Parnicka Z, Kurca E, Dobrota D, Lehotsky J (2015) The association of HLA-DRB1 and HLA-DQB1 alleles with genetic susceptibility to multiple sclerosis in the Slovak population. Neurol Res 37:1060–1067
Hauser SL, Oksenberg JR, Lincoln R, Garovoy J, Beck RW, Cole SR, Moke PS, Kip KE, Gal RL, Long DT (2000) Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS. Optic Neuritis Study Group. Neurology 54:1859–1861
Zivadinov R, Uxa L, Zacchi T, Nasuelli D, Ukmar M, Furlan C, Pozzi-Mucelli R, Tommasi MA, Locatelli L, Ulivi S, Bratina A, Bosco A, Grop A, Cazzato G, Zorzon M (2003) HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J Neurol 250:1099–1106. doi:10.1007/s00415-003-0164-7
Cocco E, Murru R, Costa G, Kumar A, Pieroni E, Melis C, Barberini L, Sardu C, Lorefice L, Fenu G, Frau J, Coghe G, Carboni N, Marrosu MG (2013) Interaction between HLA-DRB1-DQB1 haplotypes in Sardinian multiple sclerosis population. PLoS One 8:e59790. doi:10.1371/journal.pone.0059790
Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, Shah TS, Patsopoulos NA, Alfredsson L, Anderson CA, Attfield KE, Baranzini SE, Barrett J, Binder TM, Booth D, Buck D, Celius EG, Cotsapas C, D’Alfonso S et al (2015) Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat Genet 47:1107–1113. doi:10.1038/ng.3395
Miretti MM, Walsh EC, Ke X, Delgado M, Griffiths M, Hunt S, Morrison J, Whittaker P, Lander ES, Cardon LR, Bentley DR, Rioux JD, Beck S, Deloukas P (2005) A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J Hum Genet 76:634–646. doi:10.1086/429393
Hauser SL, Oksenberg JR (2006) The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52:61–76. doi:10.1016/j.neuron.2006.09.011
Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, Khan O, Lincoln RR, Swerdlin A, Mignot E, Lin L, Goodin D, Erlich HA, Schmidt S, Thomson G, Reich DE, Pericak-Vance MA, Haines JL, Hauser SL (2004) Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 74:160–167. doi:10.1086/380997
Healy BC, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C, Gauthier S, Buckle G, Houtchens M, Stazzone L, Khoury S, Hartzmann R, Fernandez-Vina M, Hafler DA, Weiner HL, Guttmann CR, De Jager PL (2010) HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology 75:634–640. doi:10.1212/WNL.0b013e3181ed9c9c
Hollsberg P, Hansen HJ, Haahr S (2003) Altered CD8+ T cell responses to selected Epstein–Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin Exp Immunol 132:137–143
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302. doi:10.1002/ana.22366
Vandevyver C, Buyse I, Philippaerts L, Ghabanbasani Z, Medaer R, Carton H, Cassiman JJ, Raus J (1994) HLA and T-cell receptor polymorphisms in Belgian multiple sclerosis patients: no evidence for disease association with the T-cell receptor. J Neuroimmunol 52:25–32
Ghabanbasani MZ, Gu XX, Spaepen M, Vandevyver C, Raus J, Marynen P, Carton H, Cassiman JJ (1995) Importance of HLA-DRB1 and DQA1 genes and of the amino acid polymorphisms in the functional domain of DR beta 1 chain in multiple sclerosis. J Neuroimmunol 59:77–82
Goris A, Walton A, Ban M, Dubois B, Compston A, Sawcer S (2008) A Taqman assay for high-throughput genotyping of the multiple sclerosis-associated HLA-DRB1*1501 allele. Tissue Antigens 72:401–403. doi:10.1111/j.1399-0039.2008.01101.x
Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J (2000) HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 48:211–219
Kouri I, Papakonstantinou S, Bempes V, Vasiliadis HS, Kyritsis AP, Pelidou SH (2011) HLA associations with multiple sclerosis in Greece. J Neurol Sci 308:28–31. doi:10.1016/j.jns.2011.06.037
Romero-Pinel L, Pujal JM, Martinez-Yelamos S, Gubieras L, Matas E, Bau L, Torrabadella M, Azqueta C, Arbizu T (2011) HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population. Eur J Neurol 18:337–342. doi:10.1111/j.1468-1331.2010.03148.x
Ballerini C, Guerini FR, Rombola G, Rosati E, Massacesi L, Ferrante P, Caputo D, Talamanca LF, Naldi P, Liguori M, Alizadeh M, Momigliano-Richiardi P, D’Alfonso S (2004) HLA-multiple sclerosis association in continental Italy and correlation with disease prevalence in Europe. J Neuroimmunol 150:178–185. doi:10.1016/j.jneuroim.2004.01.015
Allen M, Sandberg-Wollheim M, Sjogren K, Erlich HA, Petterson U, Gyllensten U (1994) Association of susceptibility to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles. Hum Immunol 39:41–48
Ciusani E, Allen M, Sandberg-Wollheim M, Eoli M, Salmaggi A, Milanese C, Nespolo A, Gyllensten U (1995) Analysis of HLA-class II DQA1, DQB1, DRB1 and DPB1 in Italian multiple sclerosis patients. Eur J Immunogenet 22:171–178
Fernandez O, Fernandez V, Alonso A, Caballero A, Luque G, Bravo M, Leon A, Mayorga C, Leyva L, de Ramon E (2004) DQB1*0602 allele shows a strong association with multiple sclerosis in patients in Malaga, Spain. J Neurol 251:440–444. doi:10.1007/s00415-004-0350-2
Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O (2000) Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 55:140–148
Zivadinov R, Weinstock-Guttman B, Zorzon M, Uxa L, Serafin M, Bosco A, Bratina A, Maggiore C, Grop A, Tommasi MA, Srinivasaraghavan B, Ramanathan M (2009) Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol 209:123–130. doi:10.1016/j.jneuroim.2009.01.023
Bergamaschi L, Leone MA, Fasano ME, Guerini FR, Ferrante D, Bolognesi E, Barizzone N, Corrado L, Naldi P, Agliardi C, Dametto E, Salvetti M, Visconti A, Galimberti D, Scarpini E, Vercellino M, Bergamaschi R, Monaco F, Caputo D et al (2010) HLA-class I markers and multiple sclerosis susceptibility in the Italian population. Genes Immun 11:173–180. doi:10.1038/gene.2009.101
Silva AM, Bettencourt A, Pereira C, Santos E, Carvalho C, Mendonca D, Costa PP, Monteiro L, Martins B (2009) Protective role of the HLA–A*02 allele in Portuguese patients with multiple sclerosis. Mult Scler 15:771–774. doi:10.1177/1352458509104588
Brynedal B, Duvefelt K, Jonasdottir G, Roos IM, Akesson E, Palmgren J, Hillert J (2007) HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One 2:e664. doi:10.1371/journal.pone.0000664
Acknowledgements
Claire Verbelen (XPE Pharma & Science) provided editorial and writing support based on direction from the authors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Ethical approval
The study was approved by the local ethics committee (Approval No.: P2013/098/B406201316929).
Rights and permissions
About this article
Cite this article
Lysandropoulos, A.P., Racapé, J., Holovska, V. et al. Human leucocyte antigen (HLA) class I and II typing in Belgian multiple sclerosis patients. Acta Neurol Belg 117, 61–65 (2017). https://doi.org/10.1007/s13760-016-0716-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13760-016-0716-0